Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) Short Interest Up 190.9% in July

Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) saw a large increase in short interest in July. As of July 31st, there was short interest totaling 135,284 shares, an increase of 190.9% from the July 15th total of 46,508 shares. Based on an average daily trading volume, of 95,778 shares, the days-to-cover ratio is currently 1.4 days.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Magnetar Financial LLC acquired a new position in shares of Drugs Made In America Acquisition II during the 4th quarter worth about $26,730,000. Glazer Capital LLC purchased a new stake in Drugs Made In America Acquisition II during the fourth quarter worth approximately $23,264,000. First Trust Capital Management L.P. acquired a new position in Drugs Made In America Acquisition II in the fourth quarter valued at approximately $20,474,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Drugs Made In America Acquisition II in the first quarter valued at approximately $19,960,000. Finally, Hudson Bay Capital Management LP purchased a new position in Drugs Made In America Acquisition II in the fourth quarter valued at approximately $19,493,000.

Analyst Ratings Changes

Several research analysts have recently commented on DMII shares. Wall Street Zen upgraded Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a report on Sunday, May 10th. Weiss Ratings raised shares of Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Drugs Made In America Acquisition II Stock Performance

Shares of NASDAQ DMII traded down $0.01 during mid-day trading on Friday, reaching $10.12. 5,125 shares of the company’s stock were exchanged, compared to its average volume of 114,100. The company’s 50-day moving average is $10.10 and its 200-day moving average is $10.03. Drugs Made In America Acquisition II has a 52-week low of $9.86 and a 52-week high of $10.20.

Drugs Made In America Acquisition II (NASDAQ:DMII) last issued its quarterly earnings data on Friday, August 14th. The company reported $0.07 earnings per share (EPS) for the quarter.

Drugs Made In America Acquisition II Company Profile

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.